General
Preferred name
Drinabant
Synonyms
AVE-1625 ()
AVE1625 ()
AVE 1625 ()
P&D ID
PD019847
CAS
358970-97-5
Tags
available
drug candidate
Drug indication
Psychotic disorder
Alzheimer disease
Drug Status
investigational
Max Phase
3.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Drinabant (AVE1625) is an orally active CB1 receptor antagonist. Drinabant (AVE1625) inhibits the agonist-stimulated calcium signal with IC50 values of 25 nM and 10 nM for the hCB1-R and rCB1-R, respectively, and is ineffective for the hCB2-R[1].
PRICE 272
DESCRIPTION Very high affinity and selective melatonin receptor agonist (Tocris Bioactive Compound Library)
DESCRIPTION Drinabant (AVE-1625) is an orally active CB1 receptor antagonist. Drinabant inhibits the agonist-stimulated calcium signal with IC50 values of 25 nM and 10 nM for the hCB1-R and rCB1-R, respectively, and is ineffective for the hCB2-R. (TargetMol Bioactive Compound Library)
Compound Sets
7
Cayman Chemical Bioactives
ChEMBL Drugs
DrugMAP
MedChem Express Bioactive Compound Library
ReFrame library
TargetMol Bioactive Compound Library
Tocris Bioactive Compound Library
External IDs
22
Properties
(calculated by RDKit )
Molecular Weight
496.06
Hydrogen Bond Acceptors
3
Hydrogen Bond Donors
0
Rotatable Bonds
6
Ring Count
4
Aromatic Ring Count
3
cLogP
5.51
TPSA
40.62
Fraction CSP3
0.22
Chiral centers
0.0
Largest ring
6.0
QED
0.45
QED
0.45
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Target
CB1R
Cannabinoid Receptor
Primary Target
CB1 Receptors
MOA
Antagonist
Pathway
GPCR/G protein
Neuronal Signaling
Source data